Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02358967 · ClinicalTrials.gov registry record · NA
Palm Tocotrienols in Chronic Hemodialysis (USA)
A NA study of Chronic Kidney Disease and End Stage Renal Disease, sponsored by Wayne State University.
- Completed
- Registry status
- NA
- Development phase
- 280
- Enrollment target
- 1
- Study location
NCT02358967: Completed NA study of Chronic Kidney Disease and End Stage Renal Disease, sponsored by Wayne State University.
NCT02358967 is a NA study of Chronic Kidney Disease and End Stage Renal Disease that has completed, run by Wayne State University. The registered enrollment target is 280 participants, below the 3,204-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02358967, a NA study of Chronic Kidney Disease and End Stage Renal Disease, has completed, sponsored by Wayne State University.
- COMPLETED
- Registry status
- NA
- Development phase
- 280 participants
- Enrollment target
- 1
- Study location
Study Summary
Patients undergoing chronic hemodialysis are at increased risk for cardiovascular disease, attributed in part to increased oxidative stress, inflammation and dyslipidemia. Intervention with a naturally occurring dietary supplement may improve certain biomarkers of inflammation and oxidative stress and improve the lipid profile.
Primary Outcome
measurement of hsCRP from blood samples
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT TRF (Tocotrienol-rich-fraction)
Study Locations (1)
Michigan
- Wayne State University - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 280 participants |
| Start Date | 2017-06-15 |
| Est. Completion | 2020-08-31 |
| Phase | NA |
What the finished NCT02358967 record still lists
NCT02358967 is an interventional study that assigns participants to a tested intervention. The registered 280 participants enrollment target is mid-sized for trials with a published cap, below the 3,204-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (91% lower).
The record links to 2 conditions, with Chronic Kidney Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02358967 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT02358967 about?
NCT02358967 is a clinical study titled "Palm Tocotrienols in Chronic Hemodialysis (USA)". Patients undergoing chronic hemodialysis are at increased risk for cardiovascular disease, attributed in part to increased oxidative stress, inflammation and dyslipidemia. Intervention with a naturally occurring dietary supplement may improve certain biomarkers of inflammation and oxidative stress a...
What is the current status of trial NCT02358967?
This trial is currently completed. It is a NA study. The enrollment target is 280 participants. The study started on 2017-06-15. Estimated completion is 2020-08-31.
What conditions does trial NCT02358967 study?
This clinical trial studies the following conditions: Chronic Kidney Disease, End Stage Renal Disease.
What interventions are being tested in trial NCT02358967?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), TRF (Tocotrienol-rich-fraction) (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02358967?
This trial is sponsored by Wayne State University, which has 163 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02358967 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Kidney Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02358967's enrollment target sits among peer trials
280 32nd of 101 higher than 70 of 101 other Chronic Kidney Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Kidney Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pivotal Study of the Velocity™ pAVF System
RECRUITING · NA
-
Intensive Patient Referral and Education Program Prior to Renal Replacement Therapy
RECRUITING · NA
-
A Stakeholder-enhanced Intervention to Improve the Decisional Partnership of Chronic Kidney Disease Dyads (IMPART)
RECRUITING · NA
-
Transforming Hemodialysis-Related Vascular Access Education
RECRUITING · NA
-
Transcutaneous Auricular Vagus Nerve Stimulation Device in CKD Population
RECRUITING · NA
-
Staged Kidney Transplantation During Combined Heart/Kidney Transplantation
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04084730 · 280 participants · Phase 2
Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer
- NCT04518657 · 280 participants · NA
Internet-Delivered Lifestyle Physical Activity Intervention for Cognitive Processing Speed in Multiple Sclerosis
- NCT04634916 · 280 participants · NA
Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System
- NCT04829617 · 280 participants · NA
Promoting Well-being and Health in Heart Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI